Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/4/2026

1. SNOW
2. AVGO
3. RARE
4. LULU
5. FIVE

6. HPE
7. SPY
8. ZS
9. IOT
10. DOCU

Get Alerts ALNA Hot Sheet

Price: $0.08 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will present a corporate update at two investor conferences in November:

Credit Suisse 27th Annual Healthcare ConferenceDate: Tuesday, November 13, 2018Time: 9:10 a.m. MT (11:10 a.m. ET)Location: Scottsdale, AZ

Evercore ISI HealthconXDate: Tuesday, November 27, 2018Time: 4:35 p.m. ETLocation: Boston, MA

Live audio webcasts of both presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor ContactHannah DeresiewiczStern Investor Relations, Inc.212-362-1200[email protected]

Media ContactAdam Daley Berry & Company Public Relations 212-253-8881[email protected]